CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
First-line CAR-T-cell consolidation after an abbreviated induction with 2 cycles of Rituximab and Ibrutinib prior to CAR-T-cell treatment and followed by 6 months of maintenance with Ibrutinib in patients with high risk MCL.
Epistemonikos ID: a5f6c7b3bb6b92e257820145b9f0db0b0de6ef34
First added on: Apr 17, 2025